Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
CA 2313063 A1 · Owner: Pfizer Products Inc. · Inventors: Mylari, Banavara Lakshman
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention is directed to methods, pharmaceutical compositions and kits comprising an aldose reductase inhibitor (ARI) a prodrug thereof or a, pharmaceutically acceptable salt of said ARI or said prodrug and a selective COX-2, inhibitor,a prodrug thereof or a pharmaceutically acceptable salt of said selective, COX-2 inhibitor or said prodrug. This invention further relates to methods of using, those pharmaceutical compositions for the treatment of diabetic complications such, as diabetic neuropathy, diabetic nephropathy diabetic retinopathy and , diabetic, cardiomyopathy.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 29, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 29, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 29, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.